Pembrolizumab Plus Y90 Radioembolization in HCC Subjects

NCT03099564 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Pembrolizumab
DEVICE: Y90 radioembolization

Sponsor

Ashwin Somasundaram

Collaborators

[object Object]
[object Object]